+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Oncology Biosimilars Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4615179
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Amgen, Inc.
  • Biocon Limited
  • Celltrion Healthcare
  • Merck & Co.
  • Novartis International AG
  • Samsung Bioepis Co. Ltd.
  • MORE
Oncology Biosimilars Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026, the global oncology biosimilars market was valued at US$ 1,651.5 Mn in 2017 expanding at a CAGR of 28.3% from 2018 to 2026.

Market Insights
According to the U.S. Food and Drug Administration (FDA), biosimilar is a biological product that is highly similar to an existing, approved reference product and has no clinically meaningful differences. Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. The number of biosimilar approvals soared in the United States as five of nine approved biosimilars across different disease conditions received U.S. FDA approval. Furthermore, U.S. witnessed the approvals of oncology biosimilars such as Amgen’s Mvasi (bevacizumab-awwb), a biosimilar to Genentech’s Avastin for the treatment of lung, colorectal, kidney, brain and cervical cancers; and Mylan’s Ogivri (trastuzumab-dkst), a biosimilar to Herceptin for treating breast cancer, gastric cancer, and gastrointestinal cancer. The USFDA is determined to increase biosimilar approvals, especially for cancer as cancer treatment imposes a high cost burden on patients. Although the prices of oncology biosimilars are less compared to biologics, the savings are not on the same scale as compared to generics and patented non-biological drugs. Savings of 20% - 30% compared to the reference biologic product have been observed in major markets such as Europe and North America, making biosimilars as a lucrative alternative.

In terms of drug class, the granulocyte colony-stimulating factor (G-CSF) held the largest share in the oncology biosimilars market owing to its early approvals in Europe and U.S. However, monoclonal antibodies class expected to grow at a highest growth rate and emerge as the largest market in 2026 due to recent approvals of Mvasi (bevacizumab-awwb) and Ogivri (trastuzumab-dkst) in the United States. Moreover, robust pipeline and patent expiration of major biologics during the forecast period would further assist the market growth of monoclonal antibodies. In terms of disease condition, neutropenia led the market due to approvals of filgrastim and Peg-filgrastim to multiple pharmaceutical companies in Europe and Asia Pacific. However, breast cancer is projected to proliferate at a humungous rate due to high prevalence of breast cancer globally and recent approval of trastuzumab in Europe and North America.

Europe dominated the global oncology biosimilars market in 2017 due to presence of approved oncology biosimilar such as filgrastim, trastuzumab and rituximab in the region. Moreover, the European Medicines Agency (EMA) have put forth guidelines for the approval of biosimilars through regulatory bodies such as European Society of Medical Oncology (ESMO). North America is anticipated to exhibit rapid growth in oncology biosimilars market due to market entry of breakthrough oncology biosimilars and vigorous pipeline expected to hit the market during the forecast period. The prominent players actively engaged in the oncology biosimilars market are Samsung Bioepis, Celltrion Inc., Biocon, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Sandoz Inc., Teva Pharmaceutical Industries Ltd., Apotex Inc., and BIOCAD. Robust pipeline and ongoing clinical trials in U.S. and Europe are driving the oncology biosimilars market. For instance, Pfizer has six biosimilars in phase III of clinical trials, testing for drugs such as Rituxan/MabThera, Herceptin, Avastin and Humira

Key Market Movements:
Rising prevalence of cancer worldwide
Recent FDA approved biosimilars contributing towards the growth of oncology biosimilars market
Patent expirations of major biologics leading to inclination of generic pharmaceutical companies to venture in biosimilars
Partnerships and collaboration between biopharmaceutical companies to increase research and development of biosimilars
Robust pipeline of oncology biosimilars anticipated to enter the market by 2020 will also assist market growth
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen, Inc.
  • Biocon Limited
  • Celltrion Healthcare
  • Merck & Co.
  • Novartis International AG
  • Samsung Bioepis Co. Ltd.
  • MORE
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Oncology Biosimilars Market Portraiture
2.2. Global Oncology Biosimilars Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Oncology Biosimilars Market, by Disease Condition, 2017 (US$ Mn)
2.4. Global Oncology Biosimilars Market Share, by Geography, 2017 (US$ Mn)

Chapter 3. Oncology Biosimilars: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Oncology Biosimilars Market, by Key Players, 2017

Chapter 4. Global Oncology Biosimilars Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Monoclonal Antibodies
4.3. Granulocyte Colony-Stimulating Factor (G-CSF)
4.4. Pipeline Analysis
4.4.1. Phase III Drug Analysis
4.4.1.1. Rituximab Biosimilar
4.4.1.2. Trastuzumab Biosimilar
4.4.1.3. Filgrastim Biosimilar
4.4.1.4. Bevacizumab Biosimilar
4.4.2. Tabular Representation of Phase I and Phase II Drugs

Chapter 5. Global Oncology Biosimilars Market, by Disease Condition, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Breast Cancer
5.3. Lung Cancer
5.4. Colorectal Cancer
5.5. Cervical Cancer
5.6. Blood Cancer
5.7. Neutropenia
5.8. Others (Brain Cancer, Stomach Cancer, etc.)

Chapter 6. Global Oncology Biosimilars Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.1.1. North America Oncology Biosimilars Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.1.2. North America Oncology Biosimilars Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.1.3. North America Oncology Biosimilars Market, by Country, 2016 – 2026 (US$ Mn)
6.1.3.1. U.S.
6.1.3.2. Canada
6.2. Europe Oncology Biosimilars Market Analysis, 2016 – 2026
6.2.1. Europe Oncology Biosimilars Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.2.2. Europe Oncology Biosimilars Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.2.3. Europe Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific Oncology Biosimilars Market Analysis, 2016 – 2026
6.3.1. Asia Pacific Oncology Biosimilars Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.3.2. Asia Pacific Oncology Biosimilars Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.3.3. Asia Pacific Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America Oncology Biosimilars Market Analysis, 2016 – 2026
6.4.1. Latin America Oncology Biosimilars Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.4.2. Latin America Oncology Biosimilars Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.4.3. Latin America Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa Oncology Biosimilars Market, 2016 – 2026
6.5.1. Middle East & Africa Oncology Biosimilars Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.5.2. Middle East &Africa Oncology Biosimilars Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.5.3. Middle East & Africa Oncology Biosimilars Market Analysis, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa

Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Mylan N.V.
7.3. Samsung Bioepis Co. Ltd.
7.4. Teva Pharmaceutical Industries Ltd.
7.5. Pfizer, Inc.
7.6. Celltrion Healthcare
7.7. Novartis International AG
7.8. Biocon Limited
7.9. Biogen Idec
7.10. Sandoz
7.11. Dr. Reddy’s Laboratory
7.12. Merck & Co.
7.13. Shanghai Henlius Biotech, Inc.
7.14. Biocad

List of Figures

FIG 1. Oncology Biosimilars Market: Research Methodology
FIG 2. Oncology Biosimilars: Market Segmentation
FIG 3. Global Oncology Biosimilars Market, by Drug Class, 2017 (US$ Mn)
FIG 4. Global Oncology Biosimilars Market, by Disease Condition, 2017 (US$ Mn)
FIG 5. Global Oncology Biosimilars Market, by Geography, 2017 (US$ Mn)
FIG 6. Attractive Investment Proposition, by Geography, 2017
FIG 7. Competitive Analysis: Global Oncology Biosimilars Market, by Key Players, 2017
FIG 8. Global Monoclonal Antibodies Market in Oncology Biosimilars, 2016-2026(US$ Mn)
FIG 9. Global Granulocyte Colony-Stimulating Factor (G-CSF) Market in Oncology Biosimilars, 2016-2026 (US$ Mn)
FIG 10. Global Rituximab Biosimilar Market in Oncology Biosimilars, 2016-2026(US$ Mn)
FIG 11. Global Trastuzumab Biosimilar Market in Oncology Biosimilars, 2016-2026 (US$ Mn)
FIG 12. Global Filgrastim Biosimilar Market in Oncology Biosimilars, 2016-2026(US$ Mn)
FIG 13. Global Bevacizumab Biosimilar Market in Oncology Biosimilars, 2016-2026 (US$ Mn)
FIG 14. Global Breast Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 15. Global Lung Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 16. Global Colorectal Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 17. Global Cervical Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 18. Global Blood Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 19. Global Neutropenia Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 20. Global Others Cancer Treatment in Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 21. U.S. Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 22. Canada Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 23. U.K. Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 24. Germany Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 25. Rest of Europe Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 26. China Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 27. Japan Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 28. Rest of Asia Pacific Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 29. Brazil Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 30. Mexico Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 31. Rest of Latin America Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 32. GCC Oncology Biosimilars Market, 2016-2026 (US$ Mn)
FIG 33. Rest of Middle East & Africa Oncology Biosimilars Market, 2016-2026 (US$ Mn)

List of Tables

TABLE 1 Global Oncology Biosimilars Market Portraiture
TABLE 2 Global Oncology Biosimilars Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Pipeline Analysis: Phase I and Phase II Drugs
TABLE 4 Global Oncology Biosimilars Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 5 Global Oncology Biosimilars Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 6 North America Oncology Biosimilars Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 7 North America Oncology Biosimilars Market, by Disease Condition, 2016 – 2026 (US$ Mn
TABLE 8 North America Oncology Biosimilars Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 9 Europe Oncology Biosimilars Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 10 Europe Oncology Biosimilars Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 11 Europe Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific Oncology Biosimilars Market, by Drug Condition, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific Oncology Biosimilars Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 14 Asia Pacific Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America Oncology Biosimilars Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America Oncology Biosimilars Market, by Disease Condition, 2016 – 2026 (US$ Mn
TABLE 17 Latin America Oncology Biosimilars Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East & Africa Oncology Biosimilars Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East & Africa Oncology Biosimilars Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 20 Middle East & Africa Oncology Biosimilars Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 21 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Samsung Bioepis Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Celltrion Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Novartis International AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Biocon Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Biogen Idec: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 Dr. Reddy’s Laboratory: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 Merck & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 Shanghai Henlius Biotech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 33 Biocad: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amgen, Inc.
  • Mylan N.V.
  • Samsung Bioepis Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Celltrion Healthcare
  • Novartis International AG
  • Biocon Limited
  • Biogen Idec
  • Sandoz
  • Dr. Reddy’s Laboratory
  • Merck & Co.
  • Shanghai Henlius Biotech, Inc.
  • Biocad
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4615179
Adroll
adroll